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 48 
SUMMARY 49 
 50 
Early in the history of schistosomiasis research, children under five years of age were 51 
known to be infected. Although this problem was recognized over one hundred years 52 
ago, insufficient action has been taken to address this issue. Under current policy, such 53 
infected children only receive their first antiparasitic treatment (praziquantel-PZQ) 54 
upon entry into primary school as current  mass drug administration (MDA) 55 
programmes typically target  school-aged children. For many infected children,  they 56 
will  wait  up to 6 years before receiving their first medication and significant 57 
schistosomiasis-related morbidity may have already established. This inequity would 58 
not be accepted for other diseases. To unveil some of the reasons behind this neglect, it 59 
is paramount to understand the intricate historical relationship between 60 
schistosomiasis and British Imperial medicine, to undertint  its lasting influence on 61 
today’s public health priorities. This review presents a  perspective on the historical 62 
neglect of  paediatric schistosomiasis, focusing on important gaps that persist from the 63 
early days after discovery of this parasite. Looking to end this inequity, we address  64 
several issues that need to be overcome to move forward towards the lasting success of 65 
schistosomiasis control and elimination efforts.   66 
 67 
 68 
 69 
 70 
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 72 
 73 
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 75 
 76 
 77 
 78 
 79 
 80 
 81 
Amaya L. Bustinduy and others                                                        Paediatric Schistosomiasis 
 
 3 
CHILDREN’S ROLE IN THE HISTORY OF SCHISTOSOMIASIS 82 
 83 
 As Farley has stated: “Tropical medicine from 1898 to the 1970s was fundamentally 84 
imperialistic in its basic assumptions, its methods, its goals and its priorities” (Farley, 85 
1991). He then elaborates on this point by stating that “..the basic goal of tropical 86 
medicine was to render the tropical world fit for white habitation and white investment”. 87 
This period broadly overlaps the time of the discovery of the Schistosoma parasite and 88 
the evolution in the biomedical community’s understanding of the parasite’s biology, 89 
transmission, and disease manifestations (Fig.1). Robert T. Leiper, one of the most 90 
prominent parasitologists of his time, detailed the African schistosome life cycle in 91 
1916, enabling him to fulfill his mandate: to prevent the transmission of schistosomiasis 92 
among British troops during World War I (Stothard et al., 2016). He did so by promoting 93 
activities to prevent contact with cercariae-infested waters. Although prevention 94 
proved to be the most effective strategy for military troops, it was largely impracticable 95 
for indigenous people whose lives depended on irrigation and farming along the Nile 96 
Delta, and so could not be enforced. 97 
 98 
In terms of the significance of disease in children, The British Colonial Office 99 
recognized the inherent risks of raising children in tropical environments where, in 100 
1893, schistosomiasis (Bilharzia) was known to be a common illness . British children 101 
were advised to be sent home “…. or they will deteriorate physically and morally, grow up 102 
slight, weedy, and delicate, with a general feebleness” (Farley, 1991). This is one of the 103 
first (indirect) descriptions of the disabling effects of schistosomiasis in children, albeit 104 
European.  105 
 106 
<< Please insert Figure 1 here>> 107 
 108 
There was a slow transition from the golden era of descriptive parasitology 109 
(1850’s-1920’s), which had a particular interest in environmental practices for disease 110 
control, toward disease-centered research, which enabled the discovery of effective 111 
drugs. Nevertheless, human Schistosoma-related disease went without an available 112 
treatment for over 50 years (Fig. 1).   The species-specific description of 113 
schistosomiasis-associated morbidity began early on, and necropsy studies primarily 114 
contributed to this knowledge of chronic Schistosoma infection (Bustinduy, 2013) (Fig. 115 
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1). As a result, the most overt organ-level morbidities, such as hepatosplenomegaly, 116 
peri-portal fibrosis, and subsequent portal hypertension with oesophageal varices, were 117 
clearly linked to S. mansoni and S. japonicum. They thus became the primary focus of 118 
population-based disease prevalence studies for intestinal forms of schistosomiasis.  119 
Haematuria and renal tract pathology (bladder polyps, hydronephrosis and associations 120 
to bladder cancer) were identified as complications of S. haematobium infection, and 121 
these became the focus of efforts for prevention and control for this species (Bustinduy, 122 
2013; Colley et al., 2014). Unfortunately, it took over 100 years to recognize the more 123 
widespread and disabling systemic morbidities of Schistosoma infection that affect the 124 
youngest age groups (King & Dangerfield-Cha, 2008; Koukounari et al., 2006; 125 
Koukounari et al., 2007; Mupfasoni et al., 2009; Parraga et al., 1996). 126 
 127 
Michael Gelfand, a clinician stationed in Rhodesia (present day Zimbabwe) in the 128 
early 1960’s, was particularly influential in describing the morbidity of the disease in 129 
children. In a detailed clinical description of intestinal schistosomiasis he reported: 130 
“This feature of tiredness stands out more in bilharziasis than in any other tropical 131 
infestation. The lethargy of the child is often noticed by teachers, who sees him becoming 132 
apathetic, falling behind in games and lacking enthusiasm.”  (Gelfand, 1967). At the time, 133 
these careful clinical observations lacked metrics to accurately measure this ‘fatigue’. 134 
Moreover, there was no strategy to treat these children en masse (Farley, 1991). Much 135 
later, the association between schistosomiasis and decreased physical fitness was 136 
documented in Coastal Kenya among boys with urogenital schistosomiasis. This study, 137 
although innovative, made use of the Harvard step-test, an instrument not validated for 138 
children (Stephenson et al., 1985b). Subsequent work in the same area has identified 139 
the 20-meter shuttle run test as an accurate and easy-to-implement field fitness test 140 
with excellent correlations between child poly-parasitic status, anaemia and decreased 141 
aerobic capacity in over 2,000 children (Bustinduy et al., 2011).  142 
 143 
Infection in very young children was particularly well described in clinical 144 
accounts from Rhodesia. Up to half of children as young as 2 years old were documented 145 
as having egg-patent infection in endemic villages, but in an era of very expensive 146 
injectable drug therapy, treating them was not even considered (Fig. 2). Only overt 147 
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morbidity was eligible for treatment and this mostly occurred among older children and 148 
adults (Gelfand, 1967).   149 
 150 
<< Please insert Figure 2 here>> 151 
 152 
In textbooks and policy literature, school-age children have been characterized 153 
as the main transmitters of Schistosoma infection due to their high egg output (peaking 154 
in mid-childhood between 10-15 years old) and increased water contact. Owing to their 155 
“careless” water use practices, which include frequent wading, playing, and urinating or 156 
defecating in or near the water, the Schistosoma transmission cycle is greatly bolstered 157 
(Mott et al., 1985; Webbe, 1982). Because detectable Schistosoma-specific morbidity due 158 
to advanced organ fibrosis is mostly seen in early adulthood, children were not 159 
considered as seriously affected by their infection status (Gryseels, 1989). In addition, 160 
risk for disease was erroneously believed to be related only to high-intensity infections. 161 
(Gryseels, 1989; Warren et al., 1979) Recent studies across Schistosoma species have 162 
discredited this paradigm by demonstrating that light-intensity infections already have 163 
tangible negative health effects (Bustinduy et al., 2013; Ezeamama et al., 2005b; King, 164 
2015).  165 
In the first wave of population-based morbidity surveys in the 1960s and 1970s, 166 
many children were wrongly classified as ‘uninfected’ due to insensitive diagnostic 167 
methods (i.e., eggs were not found in urine or stool), and they were termed 168 
‘asymptomatic’ when overt anatomic morbidity was absent. (Mott, 2004; Mott & Cline, 169 
1980) More refined seroprevalence studies have now demonstrated that almost all 170 
children from highly endemic areas are infected by the time they reach puberty (Colley 171 
et al., 2014). Sadly, this misclassification of infection status has confounded accurate 172 
burden of disease estimates and has delayed recognition of Schistosoma infection as a 173 
major cause of disease/disability burden in endemic countries. (King, 2010; King, 2015) 174 
Novel diagnostic assays, the Circulating Cathodic Antigen (CCA) and the Circulating 175 
Anodic Antigen (CAA), which are able to detect circulating Schistosoma antigens from as 176 
little as one worm pair, are now revealing clinically significant worm burdens in 177 
individuals who were previously thought to be ‘uninfected’ based on egg-count testing.  178 
(Colley et al., 2013; van Dam et al., 2015) 179 
 180 
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THE FIRST NUTRITIONAL STUDIES 181 
The first nutritional studies in the 1980s were seminal in the field of paediatric 182 
schistosomiasis.  Conducted in Coastal Kenya by Stephenson and Latham, they opened 183 
the door to rigorous research in this area. Epidemiological correlations were made 184 
between parasitic infections, including S. haematobium, and delayed growth 185 
(Stephenson et al., 1985a). Children showed dramatic improvements in appetite and 186 
physical fitness after a single dose of metrifonate, an drug effective against S. 187 
haematobium that was used in that era. (Latham et al., 1990) Unfortunately, little had 188 
changed in the same area of Kenya over the next 25 years, when further studies, 189 
applying more accurate morbidity metrics, confirmed that decreased fitness and 190 
undernutrition were still highly prevalent among children infected with S. 191 
haematobium.   (Bustinduy et al., 2013; Bustinduy et al., 2011).  192 
Progress in this field has been slow but steady. Nutritional studies of the impact 193 
of S. japonicum infection led by McGarvey and colleagues at Brown University in 194 
collaboration with researchers in the Philippines and China, have highlighted the 195 
relationship between S. japonicum infection and increased systemic inflammation 196 
within the human body, which is associated with a negative impact on growth. 197 
(McGarvey et al., 1992; McGarvey et al., 1996). Later studies have shown (partial) 198 
reversibility of malnutrition after treatment, particularly among those children who are 199 
clinically wasted at baseline. (Coutinho et al., 2006a)  200 
 201 
FUNCTIONAL MORBIDITIES AFFECTING GROWTH 202 
Advances in the knowledge of host-parasite immune responses have revealed that 203 
schistosomiasis is fundamentally a chronic inflammatory disease that affects the entire 204 
body. This has led to much wider recognition of morbidities that are linked to the pro-205 
inflammatory state that precedes fibrosis (Coutinho et al., 2006b; Leenstra et al., 2006; 206 
Wamachi et al., 2004). These so-called ‘subtle’ morbidities perhaps should be better 207 
termed ‘functional’ morbidities, as they impair normal physiological functioning of an 208 
infected child. The impact of infection on growth hormone (GH)/insulin-like growth 209 
factor-1 (IGF-1) pathways is anabolic to the skeleton, and other inflammatory cytokines 210 
also compromise bone growth (Farquharson & Ahmed, 2013). Linear growth can be 211 
severely impaired by any chronic inflammation, including inflammation caused by 212 
schistosomiasis, and this, in turn, leads to childhood growth stunting. Associated 213 
Amaya L. Bustinduy and others                                                        Paediatric Schistosomiasis 
 
 7 
anaemia of inflammation caused by infection with all species of Schistosoma impairs 214 
iron storage release and utilization (Ezeamama et al., 2005b; Koukounari et al., 2006) 215 
and this complication most readily manifests itself as decreased physical fitness 216 
(Bustinduy et al., 2011; Friedman et al., 2005; Stephenson et al., 1985b), poor 217 
concentration, and diminished school performance (Ezeamama et al., 2005a; Jukes et al., 218 
2002; Nokes et al., 1999). If untreated, these manifestations become irreversible with 219 
significant lifetime consequences: decreased work productivity as adults, altered 220 
fertility in both men and women (Kjetland et al., 2012) and decreased quality of life. 221 
(Terer et al., 2013) The misfortune behind the failure to recognize such ‘functional’ 222 
morbidities is that, because they are confounded by other co-endemic diseases, 223 
particularly malaria, they are often not adequately recognized as schistosomiasis-224 
related manifestations.  225 
 226 
There is a ‘magic window’ of opportunity to treat children who have suffered a 227 
growth arrest. This is the ‘catch up’ growth period, when a child can accelerate growth 228 
to achieve normal weight and height after an acute health insult, such as 229 
schistosomiasis. (Gurarie et al., 2011) This window closes when the growth plates fuse, 230 
and therefore early intervention is essential to achieve normal height. (Fig. 3)  231 
 232 
<< Please insert Figure 3 here>> 233 
 234 
ASSOCIATED DISABILITY IN CHILDREN 235 
Why has the negative impact of paediatric schistosomiasis been undervalued? Part of 236 
what makes schistosomiasis a ‘neglected’ disease (i.e., counted among the NTDs) is that 237 
its perceived importance to health has been linked to its disability-adjusted life-year 238 
(DALY) ranking in the WHO-World Bank Global Burden of Disease (GBD) system. In its 239 
first iteration, the GBD program intentionally weighted disease impact by age, giving 240 
much greater emphasis to diseases that affect 20-30 year olds, and much less to 241 
diseases of children under five (Murray CJ, 1996). While this error has been corrected in 242 
more recent GBD versions (Salomon et al., 2012; Vos et al., 2012) schistosomiasis has 243 
always been assigned the health impact associated with ‘minor infections’ and given a 244 
negligible 0.004-0.005 disability weight. Thus, although there are more than 250 million 245 
persons with active (egg-positive) cases, and likely an equivalent number of people with 246 
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‘egg-negative’ Schistosoma-related disease, the calculated worldwide DALY impact of 247 
schistosomiasis is perceived as less than one-tenth of that attributed to other, more 248 
lethal diseases of childhood. In the eyes of many donors and policymakers, this lowers 249 
its priority for control and prevention. 250 
 251 
To correctly assess the disease burden of Schistosoma infection it is important to 252 
recognize the lifetime cumulative impact of infection, not just in terms of individual 253 
organ pathology and dysfunction, but also on the overall whole-body performance of 254 
the growing child and young adult. Schistosomiasis that causes chronic anemia, growth 255 
faltering, and poor cognitive performance is quite disabling in a setting where resources 256 
are limited, and accommodation for disabilities is inadequate. Disease impact does not 257 
end when Schistosoma infection ends, and the associated loss of schooling and/or 258 
reduced growth cannot be reversed by childhood treatments if rapid reinfection is likely 259 
where a child lives, plays, and works. Similarly, these losses cannot be reversed once a 260 
person reaches adulthood. Once the child passes school age, most of these functional 261 
pathologies become irreversible. 262 
 263 
EARLY YEARS (< 5 YEARS OF AGE)  264 
The institutional apathy regarding treatment of schistosomiasis in children under six is 265 
in stark contrast to the recommendations for treatment of preschool children infected 266 
with soil-transmitted helminths, a practice that has been at the forefront of paediatric 267 
care and treatment campaigns for many years (World Health Organisation, 2007). 268 
Children under five years of age are often daily exposed to infected water very early in 269 
life, and although initial infection occurs ‘silently’, it generates inflammation that 270 
predisposes to organ fibrosis, which will then endure for decades (Colley et al., 2014) 271 
Fig 4. This lack of recognition dates back to early WHO reports on schistosomiasis, in 272 
which disease among very young children was described, but then appears to have been 273 
forgotten in subsequent formulation of action plans (Mott, 1982). The justification for 274 
this health policy gap was two-fold; firstly, young children were considered a lightly-275 
infected population and therefore thought to be at low-risk for schistosomiasis-276 
associated morbidity; secondly, there was no child-friendly formulation for oral 277 
treatment that would decrease the risk of choking. Crushing tablets to treat younger 278 
children was not considered practical for national programmes, although this approach 279 
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is widely performed for pill treatment of other diseases such as tuberculosis (Pineiro 280 
Perez et al., 2016). In essence, the under-fives weren’t seriously considered at risk and 281 
they were deemed too difficult and unsafe to treat, so they were excluded. It wasn’t until 282 
2010 that the first expert meeting on the inclusion of preschool children in 283 
schistosomiasis control efforts was convened at the World Health Organisation (WHO). 284 
(World Health Organization., 2011)  285 
 286 
<< Please insert Figure 4 here>> 287 
 288 
From a modern perspective, stronger evidence is emerging that very young 289 
preschool children do indeed harbor egg-patent infection. (Bosompem et al., 2004; 290 
Odogwu et al., 2006; Sousa-Figueiredo et al., 2008; Verani et al., 2011) and also present 291 
with early fibrosis, including hepatosplenic disease due to S. mansoni and early bladder 292 
changes due to S. haematobium (Fig 5). Detection of these early fibrotic changes 293 
however, may prove challenging.  294 
 295 
A recent study in Gabon, piloting a novel protocol for clinical bedside ‘Focused 296 
Assessment with Sonography in Urogenital Schistosomiasis’ (FASUS), showed a 41% 297 
prevalence of ultrasound detectable urinary tract morbidity in under-fives in a S. 298 
haematobium endemic area (Jonathan Remppis et al, manuscript in preparation). This 299 
protocol was derived from the WHO’s Niamey ultrasound protocol, widely used in 300 
prevalence studies, but not validated as a clinical tool for morbidity assessment in 301 
individual patients presenting with symptoms of S. haematobium infection. With the 302 
increasing availability of low-cost ultrasound in endemic areas, this approach could 303 
provide a point-of-care morbidity detection tool that could allow better definition of the 304 
risk of early childhood pathology. (Belard et al., 2016; Richter et al., 2016)   305 
 306 
<< Please insert Figure 5 here>> 307 
 308 
THE EVOLUTION OF ANTI-SCHISTOSOMAL TREATMENT  309 
The first injectable anti-schistosomal treatment, potassium antimony tartrate, or tartar 310 
emetic (TE), which contained trivalent antimony, was introduced in 1918 as a drug 311 
initially used to treat visceral leishmaniasis. (Christopherson, 1924) (Figure 1) 312 
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Although promising at first, it had very limited efficacy and severe side effects (Jordan, 313 
2000).  Other drugs followed, including hycanthone, and oral niridazole each with 314 
severe side effects and difficulties in administration.  Table 1 summarizes the different 315 
anti-schistosomal treatments through time.  316 
 317 
<<Please insert Table 1 here>> 318 
 319 
Since 1984, praziquantel (PZQ), the current drug of choice, has displaced older drugs of 320 
lesser effectiveness for all types of schistosomiasis. (Doenhoff et al., 2008; King et al., 321 
1988; King & Mahmoud, 1989) Its full mechanism of action remains unclear, but it is 322 
thought to act on the calcium ion channels of schistosome‘s tegument leading to 323 
disruption of the parasite’s surface, and exposing it to lethal damage by the host’s 324 
immune system (Doenhoff et al., 2008). Adult dose finding studies in the 1970’s and 325 
1980’s concluded that a single PZQ dose of 40 mg/kg was effective for treating S. 326 
haematobium and S. mansoni (Davis et al., 1979; Davis & Wegner, 1979; King et al., 327 
2002). However, in highly-endemic areas, a more intense, repeated dosing approach is 328 
likely needed for optimal effect, particularly for S. mansoni (King et al., 2011).  329 
 330 
 Since its introduction in the 1980s, praziquantel has been used safely in children. 331 
However, their recommended dosages were directly extrapolated from 332 
pharmacokinetic studies performed in adults (Kabatereine et al., 2007; Mutapi et al., 333 
2011; Xiao, 2005).  Work in Uganda in 2010 revealed sub-optimal PZQ cure rates for S. 334 
mansoni among preschool children (Sousa-Figueiredo et al., 2010). To explore the 335 
appropriateness of age-adjusted dosing, the first pharmacokinetic/pharmacodynamic 336 
PZQ study in children in Uganda was conducted in that same area. Results from this 337 
recent study showed a very concerning risk of underdosing of children, particularly the 338 
younger ones, if standard 40 mg/kg was given. Higher doses may be needed for treating 339 
these and other children infected with S. mansoni. (Bustinduy et al., 2016a)  340 
 341 
<< Please insert Figure 6 here>> 342 
 343 
 344 
 345 
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EXPANDING ACCESS TO PZQ FOR PRESCHOOL CHILDREN 346 
In response to the recommendations from the WHO expert consultation in 2011, (World 347 
Health Organization., 2011) an international, non-profit, public-private partnership, 348 
called the Praziquantel Consortium has been formed 349 
(www.paediatricpraziquantelconsortium.org). Its primary objective is to develop, 350 
register, and provide access to a new and more palatable paediatric (orodispersible) 351 
formulation of PZQ that can be used to treat young children, including infants and 352 
toddlers under the age of 6 years. More importantly, data on the treatment of very 353 
young children has been sparse and insufficient to define and confirm the best dosing 354 
regimens for young children. These factors mandated the need for the Paediatric PZQ 355 
Formulation Program to go through a full clinical drug development pathway. Currently, 356 
a Phase 2 study is being conducted in infected preschool children in Ivory Coast. To 357 
complement the product development aspects of the program, the consortium has also 358 
started to explore means to provide access to the new paediatric treatment as soon as it 359 
is marketed. (Bustinduy et al., 2016b) 360 
 361 
THE DOUBLE TREATMENT GAP IN MDA PROGRAMMES 362 
The success of schistosomiasis control programmes has been very uneven over the last 363 
century.  Efficacy has varied largely depending on the baseline prevalence of infection. 364 
(Jordan, 2000; Wang et al., 2008), Success stories in Japan, Morocco, (Amarir et al., 365 
2011) Iran, and Tunisia give hope to less developed countries that are confronted by the 366 
‘trap’ of self-perpetuating, disease-related poverty (Sacks, 2005). Economically 367 
disadvantaged countries are only just now starting to prioritize NTD control (Savioli et 368 
al., 2009). To date, implementation of large-scale control efforts in highly endemic areas 369 
has not shown permanent success, likely due to ecological factors favoring transmission 370 
and human reinfection. Part of the unfortunate lack of success of many control efforts 371 
stems from the complex reality of a disease that involves social interactions in hot spots 372 
of high transmission. Campaigns frequently miss ‘super-spreaders‘- children and 373 
individuals highly infected who act as reservoirs (King, 2009). The risk of reinfection or 374 
‘re-worming’ in high-transmission villages in Kenya was found to be as high as 50 % 375 
over two years despite ongoing school-based MDA (Satayathum et al., 2006). Even more 376 
disheartening was the return to high prevalence in the same areas after control efforts 377 
were interrupted for 8 years. (Wang et al., 2012) Older control interventions, based on 378 
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better access to clean water and the use of molluscicides, may still have important 379 
adjuvant roles to play as part of adaptive strategies in implementing more effective 380 
schistosomiasis control programs.  (Fenwick et al., 2009; Garba et al., 2009) 381 
 382 
The WHO estimates that in the 52 countries in need of schistosomiasis control, 383 
over 123 million of school-age children need preventive chemotherapy, out of which 384 
only 43 million school age children (34.6 %) may actually receive it. (World Health 385 
Organization., 2016) Therefore, there is a large treatment gap remaining among this age 386 
group. Because current control strategies primarily target children who attend school, 387 
those remaining at home, often with more severe disease, don’t necessarily receive 388 
treatment from MDA.  A vicious cycle of heavier infection and more severe morbidity 389 
ensues (Stothard, 2013; Stothard et al., 2011). This double treatment gap (preschool 390 
children and absent school age children) is a health inequality that should be a priority 391 
in control program planning and implementation. Ambitious goals set by the WHO 2012 392 
roadmap (Stothard et al., 2014; World Health Organization., 2012) have increased 393 
funding and raised the profile of schistosomiasis control, but this leaves a long road 394 
ahead for true elimination.  395 
 396 
CONCLUSIONS 397 
While there has not been a failure to recognize early childhood Schistosoma-related 398 
disease, treatment strategies have not been focused on this phase of infection and its 399 
spectrum of disease. It is time for this to change. While MDA continues to lower 400 
Schistosoma prevalence, the residual morbidity is significant and persistent low-level 401 
worm burdens hinder the plans for elimination in many endemic areas. A more 402 
comprehensive integrated management of schistosomiasis, including effective MDA of 403 
both preschool and school age children, needs to be adopted as a better strategy for 404 
control.  405 
 406 
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Table 1: Different anti-schistosomal treatments through time. 878 
Drug Active for 
Species 
Route of 
administratio
n 
Main  
Side effects 
Severe 
Complications 
Ref. 
Tartar emetic 
(TE) 
S. mansoni 
S.haematobium 
S.japonicum 
Intravenous 
 Nausea 
 Vomiting 
 Muscle,joint  
pain 
 T-wave 
inversion 
 Encephalopathy 
 Collapse 
 Rash 
 Hepatitis C 
(Christopherson, 
1918; Davis, 1968; 
Frank et al., 2000) 
Lucanthone 
(Miracil D ®) 
S. mansoni 
S.haematobium 
S.japonicum 
Oral 
 Nausea 
 Vomiting 
 Anxiety 
 Lethargy 
(Blair et al., 1949; 
Lees, 1966; 
Newsome & 
Halawani, 1950) 
Hycanthione 
S. mansoni 
S.haematobium 
S.japonicum 
Intramuscular 
 Nausea 
 Vomiting 
 
 Malignancy 
(Cook et al., 1977; 
Moore, 1972; 
Warren et al., 1978) 
Niridazole 
(Ambilhar®) 
S. mansoni 
S.haematobium 
S.japonicum 
Oral 
 Nausea 
 Vomiting 
 Headache 
 Vivid 
dreams 
 Acute 
confusion 
 Seizures 
 Malignancy 
 Death 
(Davis, 1966; 
Nicholson & 
McMahon, 1966) 
Metrifonate S.haematobium Oral 
 Nausea 
 Vomiting 
 
 Bronchospasm 
 Bradycardia 
 Ataxia 
 Respiratory  
paralysis 
(King et al., 1988; 
King et al., 1990) 
Oxamniquine 
S. mansoni 
 
Oral 
 Nausea 
 Vomiting 
 Dizziness 
 Drowsiness 
 Eosinophili
a 
 Seizures 
 Hallucinations 
 
(da Silva et al., 1975; 
Ferrari et al., 2003) 
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Praziquantel 
S. mansoni 
S.haematobium 
S.japonicum 
Oral 
 Nausea 
 Vomiting 
 Abdominal 
pain 
 Headache 
 Dizziness 
 Drowsiness 
  Lethargy 
(Davis et al., 1979; 
King et al., 2002) 
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